Logo image of PROK

PROKIDNEY CORP (PROK) Stock Fundamental Analysis

NASDAQ:PROK - US74291D1046 - Common Stock

2.49 USD
+0.11 (+4.62%)
Last: 8/27/2025, 8:12:43 PM
2.4509 USD
-0.04 (-1.57%)
Pre-Market: 8/28/2025, 8:24:18 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PROK. PROK was compared to 547 industry peers in the Biotechnology industry. PROK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PROK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PROK had negative earnings in the past year.
In the past year PROK has reported a negative cash flow from operations.
In the past 5 years PROK always reported negative net income.
PROK had a negative operating cash flow in each of the past 5 years.
PROK Yearly Net Income VS EBIT VS OCF VS FCFPROK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -19.48%, PROK is doing good in the industry, outperforming 77.51% of the companies in the same industry.
Industry RankSector Rank
ROA -19.48%
ROE N/A
ROIC N/A
ROA(3y)-14.39%
ROA(5y)-68.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROK Yearly ROA, ROE, ROICPROK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PROK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROK Yearly Profit, Operating, Gross MarginsPROK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

4

2. Health

2.1 Basic Checks

PROK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PROK has more shares outstanding
The debt/assets ratio for PROK has been reduced compared to a year ago.
PROK Yearly Shares OutstandingPROK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PROK Yearly Total Debt VS Total AssetsPROK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

PROK has an Altman-Z score of -4.98. This is a bad value and indicates that PROK is not financially healthy and even has some risk of bankruptcy.
PROK has a Altman-Z score of -4.98. This is comparable to the rest of the industry: PROK outperforms 40.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.98
ROIC/WACCN/A
WACC9.72%
PROK Yearly LT Debt VS Equity VS FCFPROK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

2.3 Liquidity

PROK has a Current Ratio of 11.48. This indicates that PROK is financially healthy and has no problem in meeting its short term obligations.
PROK's Current ratio of 11.48 is amongst the best of the industry. PROK outperforms 84.64% of its industry peers.
A Quick Ratio of 11.48 indicates that PROK has no problem at all paying its short term obligations.
PROK has a Quick ratio of 11.48. This is amongst the best in the industry. PROK outperforms 84.64% of its industry peers.
Industry RankSector Rank
Current Ratio 11.48
Quick Ratio 11.48
PROK Yearly Current Assets VS Current LiabilitesPROK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.39% over the past year.
EPS 1Y (TTM)3.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.42% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.08%
EPS Next 2Y7.83%
EPS Next 3Y4.57%
EPS Next 5Y8.42%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PROK Yearly Revenue VS EstimatesPROK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PROK Yearly EPS VS EstimatesPROK Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PROK. In the last year negative earnings were reported.
Also next year PROK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROK Price Earnings VS Forward Price EarningsPROK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROK Per share dataPROK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.83%
EPS Next 3Y4.57%

More info and screens

0

5. Dividend

5.1 Amount

PROK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROKIDNEY CORP

NASDAQ:PROK (8/27/2025, 8:12:43 PM)

Premarket: 2.4509 -0.04 (-1.57%)

2.49

+0.11 (+4.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners42.02%
Inst Owner Change-26.92%
Ins Owners4.31%
Ins Owner Change2.47%
Market Cap732.76M
Analysts76.92
Price Target5.95 (138.96%)
Short Float %7.88%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.29%
Min EPS beat(2)11.49%
Max EPS beat(2)19.08%
EPS beat(4)3
Avg EPS beat(4)6.08%
Min EPS beat(4)-12.23%
Max EPS beat(4)19.08%
EPS beat(8)6
Avg EPS beat(8)10.19%
EPS beat(12)10
Avg EPS beat(12)25.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.17%
PT rev (3m)21.53%
EPS NQ rev (1m)1.62%
EPS NQ rev (3m)N/A
EPS NY rev (1m)8.37%
EPS NY rev (3m)12.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)97.1%
Revenue NY rev (3m)136.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1390.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS-3.41
TBVpS-3.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.39%
ROA(5y)-68.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 525.06%
Cap/Sales 6102.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.48
Quick Ratio 11.48
Altman-Z -4.98
F-Score2
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)497.21%
Cap/Depr(5y)464.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y18.08%
EPS Next 2Y7.83%
EPS Next 3Y4.57%
EPS Next 5Y8.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.96%
EBIT Next 3Y-3.17%
EBIT Next 5YN/A
FCF growth 1Y-72.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.91%
OCF growth 3YN/A
OCF growth 5YN/A